Annovis Bio (ANVS) Expected to Announce Earnings on Friday

Annovis Bio (NYSE:ANVS) will likely be posting its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect Annovis Bio to post earnings of ($0.36) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 12:00 AM ET.

Annovis Bio (NYSE:ANVS) last issued its earnings results on Tuesday, August 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Annovis Bio Price Performance

ANVS opened at $1.99 on Friday. The company has a market capitalization of $48.52 million, a P/E ratio of -0.97 and a beta of 1.61. The firm’s fifty day moving average price is $2.16 and its two-hundred day moving average price is $2.29. Annovis Bio has a fifty-two week low of $1.11 and a fifty-two week high of $8.93.

Analysts Set New Price Targets

Several research firms recently issued reports on ANVS. Zacks Research raised shares of Annovis Bio to a “hold” rating in a research report on Friday, August 8th. HC Wainwright dropped their target price on Annovis Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, September 3rd. Canaccord Genuity Group restated a “buy” rating and set a $17.00 target price on shares of Annovis Bio in a research report on Tuesday, September 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Annovis Bio in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Annovis Bio has an average rating of “Hold” and a consensus price target of $13.50.

Institutional Investors Weigh In On Annovis Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of Annovis Bio by 20.1% during the second quarter. Geode Capital Management LLC now owns 183,287 shares of the company’s stock worth $398,000 after purchasing an additional 30,674 shares in the last quarter. JPMorgan Chase & Co. raised its position in Annovis Bio by 69.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,900 shares of the company’s stock worth $32,000 after purchasing an additional 6,100 shares during the last quarter. Marshall Wace LLP acquired a new position in Annovis Bio during the 2nd quarter worth $197,000. Finally, Jane Street Group LLC bought a new position in Annovis Bio in the 2nd quarter valued at $52,000. Institutional investors and hedge funds own 15.83% of the company’s stock.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.